Key result
Trimetazidine showed no significant difference in primary endpoint events compared to placebo in angina patients who recently underwent percutaneous coronary intervention.
Why the study?
Does trimetazidine improve outcomes compared to placebo in angina patients who recently underwent percutaneous coronary intervention?
Does trimetazidine improve outcomes compared to placebo in angina patients who recently underwent percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
Despite the null results of the ATPCI study, trimetazidine may still have a role in symptomatic CAD patients due to study design and population limitations.
RESULTS: of the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by Percutaneous Coronary Intervention (ATPCI) study showed no significant difference in the incidence of primary endpoint events between trimetazidine and placebo group in angina patients who recently underwent percutaneous coronary intervention. However, the study had limitations specific to both, design and selection of patient population. Here, we present some explanations for the null effects of trimetazidine in the ATPCI study and their relevance in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Dalal et al. (2020) conducted an editorial in Angina pectoris. Trimetazidine vs. Placebo was evaluated on Primary endpoint events. Trimetazidine showed no significant difference in primary endpoint events compared to placebo in angina patients who recently underwent percutaneous coronary intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: